Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.
July 01, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience and maintained a $14 price target.
The reiteration of an Overweight rating and a maintained price target of $14 by a reputable analyst can boost investor confidence in Skye Bioscience, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100